Apolipoprotein AII amyloidosis

WikiDoc Resources for Apolipoprotein AII amyloidosis

Articles

Most recent articles on Apolipoprotein AII amyloidosis

Most cited articles on Apolipoprotein AII amyloidosis

Review articles on Apolipoprotein AII amyloidosis

Articles on Apolipoprotein AII amyloidosis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Apolipoprotein AII amyloidosis

Images of Apolipoprotein AII amyloidosis

Photos of Apolipoprotein AII amyloidosis

Podcasts & MP3s on Apolipoprotein AII amyloidosis

Videos on Apolipoprotein AII amyloidosis

Evidence Based Medicine

Cochrane Collaboration on Apolipoprotein AII amyloidosis

Bandolier on Apolipoprotein AII amyloidosis

TRIP on Apolipoprotein AII amyloidosis

Clinical Trials

Ongoing Trials on Apolipoprotein AII amyloidosis at Clinical Trials.gov

Trial results on Apolipoprotein AII amyloidosis

Clinical Trials on Apolipoprotein AII amyloidosis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Apolipoprotein AII amyloidosis

NICE Guidance on Apolipoprotein AII amyloidosis

NHS PRODIGY Guidance

FDA on Apolipoprotein AII amyloidosis

CDC on Apolipoprotein AII amyloidosis

Books

Books on Apolipoprotein AII amyloidosis

News

Apolipoprotein AII amyloidosis in the news

Be alerted to news on Apolipoprotein AII amyloidosis

News trends on Apolipoprotein AII amyloidosis

Commentary

Blogs on Apolipoprotein AII amyloidosis

Definitions

Definitions of Apolipoprotein AII amyloidosis

Patient Resources / Community

Patient resources on Apolipoprotein AII amyloidosis

Discussion groups on Apolipoprotein AII amyloidosis

Patient Handouts on Apolipoprotein AII amyloidosis

Directions to Hospitals Treating Apolipoprotein AII amyloidosis

Risk calculators and risk factors for Apolipoprotein AII amyloidosis

Healthcare Provider Resources

Symptoms of Apolipoprotein AII amyloidosis

Causes & Risk Factors for Apolipoprotein AII amyloidosis

Diagnostic studies for Apolipoprotein AII amyloidosis

Treatment of Apolipoprotein AII amyloidosis

Continuing Medical Education (CME)

CME Programs on Apolipoprotein AII amyloidosis

International

Apolipoprotein AII amyloidosis en Espanol

Apolipoprotein AII amyloidosis en Francais

Business

Apolipoprotein AII amyloidosis in the Marketplace

Patents on Apolipoprotein AII amyloidosis

Experimental / Informatics

List of terms related to Apolipoprotein AII amyloidosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  Fahimeh Shojaei, M.D.

Synonyms and keywords:

## Overview[edit | edit source]

## Historical Perspective[edit | edit source]

* In 1639, Nicolaus Fontanus autopsied a young man who had ascites, jaundice, liver abscess, and splenomegaly and his report has been the first description of amyloidosis.[1]
* In 1854, Rudolph Virchow introduced the term "amyloid" as a macroscopic abnormality in some tissues.[2]
* In 1867, Weber reported the first case of amyloidosis associated with multiple myeloma.[1]
* In 1922, Bennhold introduced Congo Red staining of amyloid that remains the gold standard for diagnosis.[3]
* In 1959, Cohen and Calkins used ultrathin sections of amyloidotic tissues and assessed by electron microscopy, explained the presence of non-branching fibrils with indeterminate length and variable width.[2][1]

## Classification[edit | edit source]

Apolipoprotein AII amyloidosis is one of the subtypes of familial amyloidosis. Familiar amyloidosis may be classified according to the type of mutant protein into 7 subtypes:[4][5][6]

* Transthyretin (TTR)
* Apolipoprotein AI
* Apolipoprotein AII
* Fibrinogen Aa
* Lysozyme
* Gelsolin
* Cystatin C

| Genes involved in familial amyloidosis|

|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|

| Transthyretin (TTR)|

| Apolipoprotein AI|

| Gelsolin|

| Lysozyme|

| Cystatin C|

| Fibrinogen Aa-chain|

| Apolipoprotein AII

## Pathophysiology[edit | edit source]

### Pathogenesis[edit | edit source]

* It is understood that amyloidosis is the result of deposition of Amyloid.[7]
* Amyloid is an abnormal insoluble extracellular protein which may cause organic dysfunction and a wide variety of clinical syndromes.
* These abnormal amyloids are derived from misfolding and aggregation of normally soluble proteins.
* Amyloid depositions also have glycosaminoglycans and serum amyloid P component (SAP) which alter the propensity for amyloid formation.[8][9][10]
* Amyloid deposition can disrupt tissue structure of involved organ and consequently leads to organ failure.[11]
* Genetic mutations in Apolipoprotein AII gene may lead to misfolding protein product.

### Genetics[edit | edit source]

* 3 different mutations in the stop codon for the ApoAII gene including stop78Gly, stop78Ser, and stop78Arg has been found to be associated with amyloidosis.
* These mutations lead to an extra 21-amino acid at the carboxyl terminal end of the protein.

## Causes[edit | edit source]

Common cause of Apolipoprotein AII amyloidosis is genetic mutation.[12][13][14][15]

## Differentiating ((Page name)) from Other Diseases[edit | edit source]

[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].

[Disease name] must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].

## Epidemiology and Demographics[edit | edit source]

* The incidence of amyloidosis is approximately 1.2 per 100,000 individuals per year worldwide.[16]

* The mortality rate of systemic amyloidosis is approximately 100 per 100,000 deaths in developed countries.[17]

* In apolipoprotein AII amyloidosis, the mean age of presentation is early adulthood.

* Hereditary amyloidosis subtypes include a substitution of an amino acid that is detected in approximately 4% of the african american population.[16]

* Men are more commonly affected by amyloidosis than women.[18]

## Risk Factors[edit | edit source]

Common risk factors in the development of apolipoprotein AII amyloidosis include:[19][20][19]

* Older age
* Male gender
* African american race
* Positive family history

## Screening[edit | edit source]

There is insufficient evidence to recommend routine screening for apolipoprotein AII amyloidosis.

## Natural History, Complications, and Prognosis[edit | edit source]

If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].

Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].

Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.

## Diagnosis[edit | edit source]

### Diagnostic Study of Choice[edit | edit source]

* Tissue biopsy with Congo red stain is the gold standard test for the diagnosis of apolipoprotein AII amyloidosis.[21]
* Biopsy tissue may be taken from an affected organ like kidney, or from subcutaneous fat or rectal mucosa.
* The rectal mucosa biopsy is more sensitive for apolipoprotein AII amyloidosis.
* Biopsy of the affected organ is recommended for patients with limited organ involvement.[22]
* Biopsy from unaffected organs is more sensitive in patients with multi-organ involvement.
* The following finding on performing tissue biopsy is confirmatory for familial amyloidosis:[23][24]
* Apple green birefringence of the tissue sample under polarized light with Congo red stain.

* There are no established criteria for the diagnosis of familial amyloidosis.

### History and Symptoms[edit | edit source]

The majority of patients with [disease name] are asymptomatic.

The hallmark of [disease name] is [finding]. A positive history of [finding 1] and [finding 2] is suggestive of [disease name]. The most common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3]. Common symptoms of [disease] include [symptom 1], [symptom 2], and [symptom 3]. Less common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3].

### Physical Examination[edit | edit source]

Patients with [disease name] usually appear [general appearance]. Physical examination of patients with [disease name] is usually remarkable for [finding 1], [finding 2], and [finding 3].

Common physical examination findings of [disease name] include [finding 1], [finding 2], and [finding 3].

The presence of [finding(s)] on physical examination is diagnostic of [disease name].

The presence of [finding(s)] on physical examination is highly suggestive of [disease name].

### Laboratory Findings[edit | edit source]

An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].

Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

[Test] is usually normal among patients with [disease name].

Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].

There are no diagnostic laboratory findings associated with [disease name].

### Electrocardiogram[edit | edit source]

There are no ECG findings associated with [disease name].

An ECG may be helpful in the diagnosis of [disease name]. Findings on an ECG suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

### X-ray[edit | edit source]

There are no x-ray findings associated with [disease name].

An x-ray may be helpful in the diagnosis of [disease name]. Findings on an x-ray suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

There are no x-ray findings associated with [disease name]. However, an x-ray may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

### Echocardiography or Ultrasound[edit | edit source]

There are no echocardiography/ultrasound findings associated with [disease name].

Echocardiography/ultrasound may be helpful in the diagnosis of [disease name]. Findings on an echocardiography/ultrasound suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

There are no echocardiography/ultrasound findings associated with [disease name]. However, an echocardiography/ultrasound may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

### CT scan[edit | edit source]

There are no CT scan findings associated with [disease name].

[Location] CT scan may be helpful in the diagnosis of [disease name]. Findings on CT scan suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

There are no CT scan findings associated with [disease name]. However, a CT scan may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

### MRI[edit | edit source]

There are no MRI findings associated with [disease name].

[Location] MRI may be helpful in the diagnosis of [disease name]. Findings on MRI suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

There are no MRI findings associated with [disease name]. However, a MRI may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].

### Other Imaging Findings[edit | edit source]

There are no other imaging findings associated with [disease name].

[Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

### Other Diagnostic Studies[edit | edit source]

There are no other diagnostic studies associated with [disease name].

[Diagnostic study] may be helpful in the diagnosis of [disease name]. Findings suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].

Other diagnostic studies for [disease name] include [diagnostic study 1], which demonstrates [finding 1], [finding 2], and [finding 3], and [diagnostic study 2], which demonstrates [finding 1], [finding 2], and [finding 3].

## Treatment[edit | edit source]

### Medical Therapy[edit | edit source]

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

The majority of cases of [disease name] are self-limited and require only supportive care.

[Disease name] is a medical emergency and requires prompt treatment.

The mainstay of treatment for [disease name] is [therapy].

OR  The optimal therapy for [malignancy name] depends on the stage at diagnosis.

[Therapy] is recommended among all patients who develop [disease name].

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

### Surgery[edit | edit source]

Surgical intervention is not recommended for the management of [disease name].

Surgery is not the first-line treatment option for patients with [disease name]. Surgery is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]

The mainstay of treatment for [disease name] is medical therapy. Surgery is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].

The feasibility of surgery depends on the stage of [malignancy] at diagnosis.

Surgery is the mainstay of treatment for [disease or malignancy].

### Primary Prevention[edit | edit source]

There are no established measures for the primary prevention of [disease name].

There are no available vaccines against [disease name].

Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].

### Secondary Prevention[edit | edit source]

There are no established measures for the secondary prevention of [disease name].

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

## References[edit | edit source]

1. ↑ 1.0 1.1 1.2 Kyle RA (June 2011). "Amyloidosis: a brief history". Amyloid. 18 Suppl 1: 6–7. doi:10.3109/13506129.2011.574354001. PMID 21838413.
2. ↑ 2.0 2.1 Sipe JD, Cohen AS (June 2000). "Review: history of the amyloid fibril". J. Struct. Biol. 130 (2–3): 88–98. doi:10.1006/jsbi.2000.4221. PMID 10940217.
3. ↑ Khan MF, Falk RH (November 2001). "Amyloidosis". Postgrad Med J. 77 (913): 686–93. PMC 1742163. PMID 11677276.
4. ↑ Benson, Merrill D (2003). "The hereditary amyloidoses". Best Practice & Research Clinical Rheumatology. 17 (6): 909–927. doi:10.1016/j.berh.2003.09.001. ISSN 1521-6942.
5. ↑ Benson, Merrill D (2003). "The hereditary amyloidoses". Best Practice & Research Clinical Rheumatology. 17 (6): 909–927. doi:10.1016/j.berh.2003.09.001. ISSN 1521-6942.
6. ↑ Scriver, Charles (2001). The metabolic & molecular bases of inherited disease. New York: McGraw-Hill. ISBN 978-0079130358.
7. ↑ Wechalekar AD, Gillmore JD, Hawkins PN (June 2016). "Systemic amyloidosis". Lancet. 387 (10038): 2641–2654. doi:10.1016/S0140-6736(15)01274-X. PMID 26719234.
8. ↑ Pepys MB, Rademacher TW, Amatayakul-Chantler S, Williams P, Noble GE, Hutchinson WL, Hawkins PN, Nelson SR, Gallimore JR, Herbert J (June 1994). "Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure". Proc. Natl. Acad. Sci. U.S.A. 91 (12): 5602–6. doi:10.1073/pnas.91.12.5602. PMC 44044. PMID 8202534.
9. ↑ Tan SY, Pepys MB (November 1994). "Amyloidosis". Histopathology. 25 (5): 403–14. doi:10.1111/j.1365-2559.1994.tb00001.x. PMID 7868080.
10. ↑ Botto M, Hawkins PN, Bickerstaff MC, Herbert J, Bygrave AE, McBride A, Hutchinson WL, Tennent GA, Walport MJ, Pepys MB (August 1997). "Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene". Nat. Med. 3 (8): 855–9. doi:10.1038/nm0897-855. PMID 9256275.
11. ↑ Wechalekar AD, Gillmore JD, Hawkins PN (June 2016). "Systemic amyloidosis". Lancet. 387 (10038): 2641–2654. doi:10.1016/S0140-6736(15)01274-X. PMID 26719234.
12. ↑ Pepys MB, Hawkins PN, Booth DR, Vigushin DM, Tennent GA, Soutar AK, Totty N, Nguyen O, Blake CC, Terry CJ (April 1993). "Human lysozyme gene mutations cause hereditary systemic amyloidosis". Nature. 362 (6420): 553–7. doi:10.1038/362553a0. PMID 8464497.
13. ↑ Benson, Merrill D (2003). "The hereditary amyloidoses". Best Practice & Research Clinical Rheumatology. 17 (6): 909–927. doi:10.1016/j.berh.2003.09.001. ISSN 1521-6942.
14. ↑ Benson, Merrill D (2003). "The hereditary amyloidoses". Best Practice & Research Clinical Rheumatology. 17 (6): 909–927. doi:10.1016/j.berh.2003.09.001. ISSN 1521-6942.
15. ↑ Scriver, Charles (2001). The metabolic & molecular bases of inherited disease. New York: McGraw-Hill. ISBN 978-0079130358.
16. ↑ 16.0 16.1 Khan MF, Falk RH (November 2001). "Amyloidosis". Postgrad Med J. 77 (913): 686–93. PMC 1742163. PMID 11677276.
17. ↑ Pepys MB (2006). "Amyloidosis". Annu. Rev. Med. 57: 223–41. doi:10.1146/annurev.med.57.121304.131243. PMID 16409147.
18. ↑ Shin YM (March 2011). "Hepatic amyloidosis". Korean J Hepatol. 17 (1): 80–3. doi:10.3350/kjhep.2011.17.1.80. PMC 3304630. PMID 21494083.
19. ↑ 19.0 19.1 Shin YM (March 2011). "Hepatic amyloidosis". Korean J Hepatol. 17 (1): 80–3. doi:10.3350/kjhep.2011.17.1.80. PMC 3304630. PMID 21494083.
20. ↑ Khan MF, Falk RH (November 2001). "Amyloidosis". Postgrad Med J. 77 (913): 686–93. PMC 1742163. PMID 11677276.
21. ↑ Benson MD, Yazaki M, Magy N (December 2002). "Laboratory assessment of transthyretin amyloidosis". Clin. Chem. Lab. Med. 40 (12): 1262–5. doi:10.1515/CCLM.2002.218. PMID 12553428.
22. ↑ Andrews TR, Colon-Otero G, Calamia KT, Menke DM, Boylan KB, Kyle RA (December 2002). "Utility of subcutaneous fat aspiration for diagnosing amyloidosis in patients with isolated peripheral neuropathy". Mayo Clin. Proc. 77 (12): 1287–90. doi:10.4065/77.12.1287. PMID 12479513.
23. ↑ COHEN AS, CALKINS E (April 1959). "Electron microscopic observations on a fibrous component in amyloid of diverse origins". Nature. 183 (4669): 1202–3. doi:10.1038/1831202a0. PMID 13657054.
24. ↑ Kyle RA (September 2001). "Amyloidosis: a convoluted story". Br. J. Haematol. 114 (3): 529–38. doi:10.1046/j.1365-2141.2001.02999.x. PMID 11552976.

Template:WikiDoc Sources